exposing Parkinson's disease's voices and faces.

Published Date: 26 Apr 2023

One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.

Read Full News

Latest News

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Study Identifies Environmental Risk Factors Significantly Associated With Neuromyelitis Optica Spectrum Disorder Isabella Ciccone, MPH

Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.

FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy Marco Meglio

The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Isabella Ciccone, MPH

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

Natalizumab Biosimilar Officially Launched in the United States Marco Meglio

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

Todays Updates

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Todays Updates

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Latest News

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.

The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

News All Time

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD Isabella Ciccone, MPH

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Treating Obstructive Sleep Apnea: Beyond CPAP and Toward Hypoglossal Nerve Stimulation Vaishal Shah, MD, MPH, FAASM, FAAP

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Building the Next Era of ALS Clinical Research and Trials Marco Meglio

Ryan Donaghy, MD, an assistant professor of neurology at Northwestern Medicine, discussed the evolving landscape of ALS clinical trials, including advances in biomarkers, genetics, and modern trial design.

NeurologyLive® Friday 5 — November 14, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 14, 2025.

Orexin Agents ORX750 and ORX142 Show Promising Early Phase 1 and 2 Data Marco Meglio

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

FDA Adds Boxed Warning, Narrows Indication for DMD Gene Therapy Isabella Ciccone, MPH

The agency has required a postmarketing observational study to monitor safety for at least 12 months following gene therapy treatment in patients with Duchenne muscular dystrophy.

Elena Grebenciucova, MD, on Evolving Standards in NMOSD Diagnosis and Management Elena Grebenciucova, MD, Marco Meglio

The assistant professor of neurology at Northwestern University explained key diagnostic, therapeutic, and management considerations for clinicians caring for patients with NMOSD across diverse and evolving clinical scenarios.

Cladribine More Effective Than S1P Receptor Modulators in Treating Relapsing-Remitting MS, Study Shows Louie Pasculli

Cladribine shows superior efficacy over S1P modulators in reducing disability progression in treatment-naive relapsing-remitting MS patients.

NeurologyLive® Brain Games: November 16, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on CAR-T therapy for autoimmune neurologic diseases!

Multidisciplinary Care Paths That Improve Neurosarcoidosis Management Spencer Hutto, MD, Marco Meglio

Spencer Hutto, MD, associate program director of the adult neurology residency at Emory University, outlined the key diagnostic nuances, treatment considerations, and emerging therapeutic strategies shaping modern neurosarcoidosis care.

This Week on NeurologyLive® — November 17, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Nerivio REN Wearable Delivers Consistent Drug-Free Relief Over 3 Years, Study Shows Louie Pasculli

A new study confirms the Nerivio REN wearable provides long-term, drug-free migraine relief without dosage increases, ensuring consistent effectiveness over 3 years.

Decoding the Circuitry That Stabilizes Memory Maps in the Hippocampus Marco Meglio

Jayeeta Basu, PhD, an assistant professor in the departments of Psychiatry and Neuroscience at NYU Langone, commented on how newly decoded entorhinal–hippocampal circuits stabilize memory maps during learning.

Clene to Submit Application for CNM-Au8 as Potential ALS Treatment Marco Meglio

Clene Nanomedicine prepares to submit an NDA for CNM-Au8, a promising ALS treatment, aiming for accelerated FDA approval by 2026.

Exploring the Growth and Challenges of Genetic Counseling Louie Pasculli, Carrie Haverty, MS, CGC

Carrie Haverty, MS, CGC, NSGC president-elect, discusses the evolving role of genetic counselors, emphasizing personalized care, gene therapy advancements, and the need for multidisciplinary integration in health care.

Recommended News For You

Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

According to research, hospitals can save money and help cancer patients by implementing a basic intervention.

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

Why breast cancer survivors don't take their medicine, and what can be done about it.

Novel Agent Effective for Cancer Wasting Disorder

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

Recommended Articles For You

Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy 

Unlocking the Secrets of Improved Ovarian Cancer Survival Rates 

Unlocking The Power Of Cangrelor To Treat Heart Disease 

Cancer Vaccines In India: The Latest Hope In The Fight Against Disease 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study reveals increase in late-stage breast cancer diagnoses in US

2.

Using AI, one can find cancer risk factors.

3.

A promising medication could slow brain tumors in children.

4.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

5.

Prostate cancer therapies: AI-based image analysis detects early organ damage

1.

Decoding the Future: Cancer Genomics and Radiomics in Oncology

2.

Improving TIVAP Use: Review of Standardization and Optimization Practices

3.

The Benefits of Understanding Haptoglobin High: What You Need to Know

4.

Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment

5.

Understanding Lymphedema: Symptoms, Causes, and Treatment 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC - Part V

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

3.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

4.

Newer Immunotherapies for Myeloma- A Comprehensive Overview

5.

Navigating the Complexities of Ph Negative ALL - Part X

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot